New hope for blistering skin disease: early trial shows promise

NCT ID NCT02226146

Completed Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 29 times

Summary

This study tested a drug called bertilimumab in 11 adults aged 60 and older with newly diagnosed bullous pemphigoid, a condition that causes painful blisters. The goal was to see if the drug is safe and can reduce disease activity. Participants received the drug and were monitored for side effects and improvement in blistering.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Iowa City, Iowa, United States
Research Site

Buffalo, New York, United States
Research Site

New York, New York, United States
Research Site

Durham, North Carolina, United States
Research Site

Cleveland, Ohio, 10900, United States
Research Site

Salt Lake City, Utah, United States
Research Site

Ramat Gan, 5262100, Israel
Research Site

Tel Aviv, 64239, Israel

Conditions

Explore the condition pages connected to this study.

PEMPHIGOID, BULLOUS